Back to School: How biopharma can reboot drug development. Access exclusive analysis here
SEPR sold $400 in convertible subordinated debentures, with a $60 million overallotment option. The debentures bear 5 percent interest,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury